* * *
– Eli Lilly admits to more than $200 million dollars worth of doctor payoffs (Natural News, Aug 15, 2012):
Prozac. Cialis. Cymbalta. If you have a television or read magazines, you’ve heard of their drugs. Eli Lilly, out of Indiana, makes billions of dollars every year off the sale of their patented chemicals, which are used to suppress the symptoms of disease in the human body. Founded by a chemist in the late 19th century; today the pharmaceutical giant has offices in 18 countries, and its products are sold in 125 countries, with revenues exceeding $20 billion annually.
WASHINGTON (Reuters) – More than 17,000 doctors and other healthcare providers have taken money from seven major drug companies to talk to other doctors about their products, a joint investigation by news organizations and non-profit groups found.
More than 380 of the doctors, nurses, pharmacists and other professionals took in more than $100,000 in 2009 and 2010, according to the investigation released on Tuesday. The report said far more doctors are likely to have taken such payments, but it documented these based on information from seven drugmakers.
The payments are not illegal and usually not even considered improper. But the investigation by journalism group ProPublica, Consumer Reports magazine, NPR radio and several publications showed doctors were sometimes urged to recommend “off-label” prescriptions of drugs, meaning using them for conditions they are not approved for.
And the report points to several studies showing that even small gifts and payments to doctors can affect their attitudes, and many companies have stopped giving out once-common gifts such as pens, cups and other objects carrying drug brand names.
“Tens of thousands of U.S. physicians are paid to spread the word about pharma’s favored pills and to advise the companies about research and marketing,” the group says in its report, available here
The groups used information from seven drugmakers — AstraZeneca, Cephalon, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Merck and Pfizer.
“Some of the companies were forced to disclose this information as a result of legal settlements; others released it voluntarily,” Consumer Reports said.
It said more than 70 other pharmaceutical companies have not disclosed payments made to doctors, although the healthcare reform law passed in March will require them to do so by 2013.
“This investigation begins to pull back the shroud on these activities,” Dr. John Santa, director of the Consumer Reports Health Ratings Center, said in a statement.
“The amount of money involved is astounding, and the ProPublica report’s account of the background of some of the physicians is disturbing.”
– Antidepressant drugs don’t work – official study (Independent)
Not only does Prozac not work, but it destroys the brain and your health.
“Side Effects: Death” is the true story of corruption, bribery and fraud written by Dr. John Virapen, who has been called THE Big Pharma Insider. During his 35 years in the pharmaceutical industry internationally (most notably as general manager of Eli Lilly and Company in Sweden), Virapen was responsible for the marketing of several drugs, all of them with side effects. Now, Virapen is coming clean and telling all of the little secrets you were never intended to know!
Big Pharma criminals of the worst kind!
Fluoride is the main ingredient in rat poison and in Prozac. It is also used in Sarin nerve gas.
Prozac could end misery of premenstrual syndrome
Millions of women could be spared the monthly misery of premenstrual syndrome by taking a small dose of the anti-depressant Prozac, a study suggests.
British researchers have discovered that the commonly prescribed pill can block the changes in the body that cause the “symptoms” of the debilitating condition, which effects three quarters of women.
And because it has already been tested, it should mean that it could be available much more quickly than new drugs that have to go through numerous safety trials.
“A lot of women have it and a lot of men are on the receiving end of it,” said Dr Thelma Lovick, who led the research at the University of Birmingham.
“Some women really suffer and their families suffer as a result. The solution could be as simple as taking a pill for a few days towards the ends of your menstrual cycle.’”
The documents also revealed Lilly officials wrote medical journal studies about Zyprexa and then asked doctors to put their names on the articles, a practice called “ghostwriting.”
Lilly employees compiled a guide to hiring scientists to write favorable articles, complained to journal editors when publication was delayed and submitted rejected articles to other outlets, according to the documents.
The drug has never been approved for use with dementia patients, according to the FDA’s Web site.
A file photograph of Eli Lilly & Co.’s schizophrenia medication, Zyprexa, in Cambridge, Massachusetts. Photographer: JB Reed/Bloomberg News
June 12 (Bloomberg) — Eli Lilly & Co. urged doctors to prescribe Zyprexa for elderly patients with dementia, an unapproved use for the antipsychotic, even though the drugmaker had evidence the medicine didn’t work for such patients, according to unsealed internal company documents.
In 1999, four years after Lilly sent study results to the U.S. Food and Drug Administration showing Zyprexa didn’t alleviate dementia symptoms in older patients, it began marketing the drug to those very people, according to documents unsealed in insurer suits against the company for overpayment.
Regulators required Lilly and other antipsychotic drug- makers in April 2005 to warn that the products posed an increased risk to elderly patients with dementia. The documents show the health dangers in marketing a drug for an unapproved use, called off-label promotion, said Sidney Wolfe, head of the health research group at Public Citizen in Washington.
“By definition, off-label means there is no clear evidence that the benefits of a drug outweigh the risks,” Wolfe said. “The reason why off-label promotion is illegal is that you can greatly magnify the number of people who will be harmed.”
In 1999, when Lilly began its marketing push, Zyprexa’s only approved use was for patients suffering from schizophrenia, according to the FDA. In 2008, Zyprexa was Lilly’s best-selling drug, with $4.7 billion in sales, while antipsychotics as a group topped U.S. drug sales last year, with $14.6 billion.
In a request for a December 2003 meeting over a proposed label change, Lilly told the FDA that data from seven studies showed Zyprexa didn’t alleviate symptoms of Alzheimer’s or other dementia.
The studies found death rates among older dementia patients taking Zyprexa were “significantly greater” than those who didn’t get the medicine, the company said, according to the unsealed documents.
Six capsules of Prozac
They are among the biggest-selling drugs of all time, the “happiness pills” that supposedly lift the moods of those who suffer depression and are taken by millions of people in the UK every year. But one of the largest studies of modern antidepressant drugs has found that they have no clinically significant effect. In other words, they don’t work.
The finding will send shock waves through the medical profession and patients and raises serious questions about the regulation of the multinational pharmaceutical industry, which was accused yesterday of withholding data on the drugs.
It also came as Alan Johnson, the Health Secretary, announced that 3,600 therapists are to be trained during the next three years to provide nationwide access through the GP service to “talking treatments” for depression, instead of drugs, in a £170m scheme. The popularity of the new generation of antidepressants, which include the best known brands Prozac and Seroxat, soared after they were launched in the late 1980s, heavily promoted by drug companies as safer and leading to fewer side-effects than the older tricyclic antidepressants.
The publication in 1994 of Listening to Prozac by Peter Kramer, in which he suggested anyone with too little “joy juice” might give themselves a dose of the “mood brightener” Prozac , lifted sales into the stratosphere.